This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of IMC-1 In Patients With Fibromyalgia

This study has been completed.
Information provided by (Responsible Party):
Innovative Med Concepts, LLC Identifier:
First received: May 7, 2013
Last updated: March 25, 2015
Last verified: March 2015
This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms.

Condition Intervention Phase
Fibromyalgia Chronic Pain Myofascial Pain Drug: IMC-1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia

Resource links provided by NLM:

Further study details as provided by Innovative Med Concepts, LLC:

Primary Outcome Measures:
  • Change in pain from baseline [ Time Frame: 16 weeks ]
    Comparison of the change from baseline in patient self reported pain scores between IMC-1 and placebo treatment, over 16 weeks of treatment

Secondary Outcome Measures:
  • Patient Global Impression of Change [ Time Frame: 16 weeks ]
    Patients will rate their global improvement over the duration of the trial

  • Fibromyalgia Impact Questionnaire [ Time Frame: 16 weeks ]

Enrollment: 143
Study Start Date: May 2013
Study Completion Date: March 2014
Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IMC-1
Experimental intervention
Drug: IMC-1
Placebo Comparator: Matching placebo


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of fibromyalgia
  • English speaker

Exclusion Criteria:

  • Rheumatologic diseases
  • Bipolar disease, OCD, severe anxiety, schizophrenia
  • Systemic infection, severe cardiac disease, chronic steroid usage
  • chronic opioid usage
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01850420

United States, Alabama
IMC Study Site
Birmingham, Alabama, United States
United States, California
IMC Study Site
Sacramento, California, United States
IMC Study Site
San Diego, California, United States
IMC Study Site
Vista, California, United States
United States, Florida
IMC Study Site
Jacksonville, Florida, United States
IMC Study Site
Tampa, Florida, United States
United States, Indiana
IMC Study Site
Evansville, Indiana, United States
IMC Study Site
Lafayette, Indiana, United States
United States, Michigan
IMC Study Site
Ann Arbor, Michigan, United States
United States, North Carolina
IMC Study Site
Raleigh, North Carolina, United States
United States, Oregon
IMC Study Site
Medford, Oregon, United States
United States, Utah
IMC Study Site
Salt Lake City, Utah, United States
Sponsors and Collaborators
Innovative Med Concepts, LLC
  More Information

Responsible Party: Innovative Med Concepts, LLC Identifier: NCT01850420     History of Changes
Other Study ID Numbers: PRID-201
Study First Received: May 7, 2013
Last Updated: March 25, 2015

Keywords provided by Innovative Med Concepts, LLC:

Additional relevant MeSH terms:
Chronic Pain
Myofascial Pain Syndromes
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases processed this record on September 21, 2017